Castleview Partners LLC Has $2.77 Million Holdings in Amgen Inc. $AMGN

Castleview Partners LLC lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 37.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,860 shares of the medical research company’s stock after selling 4,763 shares during the quarter. Amgen comprises about 1.4% of Castleview Partners LLC’s investment portfolio, making the stock its 14th largest holding. Castleview Partners LLC’s holdings in Amgen were worth $2,766,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in AMGN. Valmark Advisers Inc. grew its position in shares of Amgen by 1.5% during the 1st quarter. Valmark Advisers Inc. now owns 8,726 shares of the medical research company’s stock worth $3,070,000 after buying an additional 133 shares during the period. Pittenger & Anderson Inc. raised its position in shares of Amgen by 2.0% in the 1st quarter. Pittenger & Anderson Inc. now owns 3,033 shares of the medical research company’s stock valued at $1,067,000 after acquiring an additional 60 shares during the period. Carnegie Investment Counsel boosted its stake in Amgen by 0.9% during the 1st quarter. Carnegie Investment Counsel now owns 107,264 shares of the medical research company’s stock worth $37,741,000 after acquiring an additional 953 shares during the last quarter. Ferguson Wellman Capital Management Inc. boosted its stake in Amgen by 1.7% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 319,238 shares of the medical research company’s stock worth $112,324,000 after acquiring an additional 5,300 shares during the last quarter. Finally, Midwest Trust Co grew its holdings in Amgen by 1.5% during the first quarter. Midwest Trust Co now owns 78,916 shares of the medical research company’s stock valued at $27,767,000 after purchasing an additional 1,150 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.85% of the stock is currently owned by company insiders.

Amgen Stock Down 0.1%

Shares of AMGN stock traded down $0.23 during trading hours on Friday, hitting $363.39. 1,632,617 shares of the company were exchanged, compared to its average volume of 2,658,015. The business has a 50 day moving average of $344.81 and a two-hundred day moving average of $349.32. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $391.29. The company has a market capitalization of $196.13 billion, a PE ratio of 25.29, a PEG ratio of 3.59 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts anticipate that Amgen Inc. will post 22.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on AMGN. Royal Bank Of Canada reiterated a “positive” rating on shares of Amgen in a report on Thursday, June 18th. Cantor Fitzgerald reissued a “neutral” rating and issued a $350.00 price target on shares of Amgen in a report on Monday, July 6th. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research report on Thursday, June 18th. Erste Group Bank reiterated a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Finally, Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $355.73.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.